Burnett, G. Leslie
Revolution Medicines (United States)
2 papers on CoChatORCID 0000-0003-2514-9373
Most cited papers
- Verified
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry
PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling
Cited by 72
- Verified
Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models
Knox, J. E., Jiang, J., Burnett, G. L., Liu, Y., Weller, C. E., Wang, Z., McDowell, L., Steele, S. L., Chin, S., Chou, K. J., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free